Last reviewed · How we verify

NCT06740656

Neuromuscular Complications of MEK Inhibitors: a French Case Series and a Systematic Review of the Literature

Not yet recruiting Last updated 18 February 2025
What this trial tests

trial testing No Interventions in Myositis in 5 participants. Not yet recruiting.

Timeline
1 March 2025
Primary endpoint
1 January 2026
1 January 2026

Quick facts

Lead sponsorCentral Hospital, Nancy, France
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment5
Start date1 March 2025
Primary completion1 January 2026
Estimated completion1 January 2026
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Central Hospital, Nancy, France

Who can join

18 and older, any sex, with Myositis or Myasthaenia Gravis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

MEK inhibitors (trametinib, cobimetinib, selumetinib or binimetinib) have been used since 2016 to treat metastatic melanoma, by targeting the MAPK pathway Neuromuscular complications (neuropathy, myasthenia or myositis) have been reported in patients treated with MEK inhibitors. With the growing use of these new oncology therapies, neurologists, oncologists and other clinicians are likely to be increasingly confronted with MEK inhibitor-induced neuropathy, myasthenia or myositis. Yet, so far, these complications have only been documented in a few single case reports. Our aim was to characterize the neuromuscular complications associated with MEK inhibitors used either alone or in combination.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No Interventions

Trials testing the same drug.

Other recruiting trials for Myositis

Currently open trials in the same condition.

Other Central Hospital, Nancy, France trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06740656.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing